Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

NCT00788151 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Dengue Virus
Dengue Fever
Dengue Hemorrhagic Fever
Dengue Diseases

Interventions

BIOLOGICAL: CYD Dengue Vaccine Serotypes 1, 2, 3, and 4
BIOLOGICAL: Pneumococcal polysaccharide vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company